BioNTech (BNTX)
(Delayed Data from NSDQ)
$112.28 USD
-0.23 (-0.20%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $113.13 +0.85 (0.76%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Balance Sheet
Fiscal Year End for BioNTech SE Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 17,911 | 14,818 | 2,454 | 1,539 | 583 |
Receivables | 2,527 | 7,529 | 14,649 | 190 | 14 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 387 | 463 | 595 | 73 | 13 |
Other Current Assets | 309 | 286 | 134 | 102 | 17 |
Total Current Assets | 21,134 | 23,097 | 17,832 | 1,904 | 627 |
Net Property & Equipment | 820 | 642 | 382 | 259 | 104 |
Investments & Advances | 1,273 | 85 | 25 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 88 | 242 | 16 | 184 | 0 |
Intangibles | 1,263 | 231 | 239 | 187 | 100 |
Deposits & Other Assets | 90 | 7 | 1 | 1 | 0 |
Total Assets | 24,900 | 24,527 | 18,729 | 2,649 | 893 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 383 | 215 | 189 | 117 | 23 |
Current Portion Long-Term Debt | 30 | 38 | 154 | 10 | 2 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 569 | 628 | 1,856 | 0 | 0 |
Other Current Liabilities | 1,259 | 2,228 | 1,920 | 565 | 130 |
Total Current Liabilities | 2,241 | 3,109 | 4,119 | 692 | 155 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 43 | 7 | 79 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 207 | 186 | 203 | 264 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 497 | 95 | 257 | 125 | 186 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2,988 | 3,396 | 4,658 | 1,082 | 341 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 269 | 262 | 291 | 281 | 260 |
Capital Surplus | 1,331 | 1,926 | 1,981 | 1,262 | 293 |
Retained Earnings | 21,390 | 19,842 | 11,692 | 0 | 0 |
Other Equity | -1,066 | -894 | 111 | 29 | 5 |
Treasury Stock | 12 | 6 | 5 | 5 | 6 |
Total Shareholder's Equity | 21,912 | 21,131 | 14,071 | 1,567 | 553 |
Total Liabilities & Shareholder's Equity | 24,900 | 24,527 | 18,729 | 2,649 | 893 |
Total Common Equity | 21,912 | 21,131 | 14,071 | 1,567 | 553 |
Shares Outstanding | 237.70 | 242.60 | 242.50 | 226.20 | 226.20 |
Book Value Per Share | 92.18 | 87.10 | 58.03 | 6.93 | 2.44 |
Fiscal Year End for BioNTech SE Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 18,626 | 17,009 | 17,911 | 17,141 | 16,964 |
Receivables | 304 | 2,077 | 2,527 | 2,494 | 3,260 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 366 | 375 | 387 | 452 | 489 |
Other Current Assets | 391 | 379 | 309 | 319 | 238 |
Total Current Assets | 19,687 | 19,840 | 21,134 | 20,407 | 20,951 |
Net Property & Equipment | 935 | 871 | 820 | 793 | 754 |
Investments & Advances | 1,493 | 1,723 | 1,273 | 1,407 | 1,499 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 110 | 99 | 88 | 227 | 261 |
Intangibles | 1,330 | 1,292 | 1,263 | 1,122 | 547 |
Deposits & Other Assets | 117 | 90 | 90 | 0 | 3 |
Total Assets | 23,948 | 24,164 | 24,900 | 24,170 | 24,235 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 949 | 324 | 383 | 242 | 249 |
Current Portion Long-Term Debt | 38 | 34 | 30 | 44 | 42 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 393 | 383 | 569 | 593 | 605 |
Other Current Liabilities | 1,232 | 1,002 | 1,259 | 1,088 | 1,087 |
Total Current Liabilities | 2,612 | 1,744 | 2,241 | 1,967 | 1,983 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 41 | 43 | 43 | 47 | 5 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 236 | 223 | 207 | 176 | 182 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 520 | 497 | 357 | 358 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 3,409 | 2,485 | 2,988 | 2,547 | 2,529 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 268 | 270 | 269 | 271 | 271 |
Capital Surplus | 1,327 | 22,449 | 1,331 | 1,337 | 1,553 |
Retained Earnings | 20,074 | 0 | 21,390 | 21,012 | 20,875 |
Other Equity | -1,118 | -1,028 | -1,066 | -985 | -984 |
Treasury Stock | 12 | 12 | 12 | 12 | 10 |
Total Shareholder's Equity | 20,539 | 21,679 | 21,912 | 21,623 | 21,706 |
Total Liabilities & Shareholder's Equity | 23,948 | 24,164 | 24,900 | 24,170 | 24,235 |
Total Common Equity | 20,539 | 21,679 | 21,912 | 21,623 | 21,706 |
Shares Outstanding | 237.70 | 237.70 | 237.70 | 239.70 | 240.90 |
Book Value Per Share | 86.41 | 91.21 | 92.18 | 90.21 | 90.10 |